Mithra Pharmaceuticals S.A.
MITPF · OTC
12/31/2023 | 6/30/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 370.8% | -87.4% | 389.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | 40.9% | -107.3% | 66.5% | -13.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -83.5% | -599.5% | -3.5% | -277.1% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -371.5% | -717.4% | -51% | -275.1% |
| EPS | -1.78 | -0.88 | -0.52 | -0.69 |
| % Growth | -102.3% | -69.2% | 24.6% | – |
| EPS Diluted | -1.78 | -0.88 | -0.52 | -0.69 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -56.5% | -484.2% | 13.3% | -191.2% |